<DOC>
	<DOCNO>NCT01393717</DOCNO>
	<brief_summary>This phase II trial study well brentuximab vedotin autologous ( take individual 's cell ) stem cell transplant work treat patient Hodgkin lymphoma . Monoclonal antibody-drug conjugate , brentuximab vedotin , block cancer growth different way target certain cell .</brief_summary>
	<brief_title>Brentuximab Vedotin Before Autologous Stem Cell Transplant Treating Patients With Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . The primary objective study determine activity salvage brentuximab vedotin Hodgkin lymphoma prior autologous hematopoietic stem cell transplantation , measure overall response rate ( ORR ) . SECONDARY OBJECTIVES : I . To describe safety , toxicity , tolerability brentuximab vedotin salvage regimen . II . To summarize stem cell mobilization result patient receive brentuximab vedotin salvage therapy ( e.g. , total cluster differentiation ( CD ) 34+ cell yield , number apheresis day , proportion patient achieve &gt; = 3 x 10^6 CD34+ cells/kg ) . III . To evaluate potential change Hodgkin lymphoma biological marker patient treat brentuximab vedotin first line salvage therapy . IV . To examine characterize outcome patient receive brentuximab vedotin first line salvage follow autologous hematopoietic stem cell transplantation ( AHCT ) ( e.g. , toxicity , 2-year progression free survival [ PFS ] , overall survival [ OS ] , relapse-progression incidence non-relapse mortality rate [ NRM ] ) OUTLINE : Patients receive brentuximab vedotin intravenously ( IV ) 30 minute day 1 . Treatment repeat every 21 day 4 course . Patients new cohort receive regular study dose brentuximab vedotin course 1 2 . Patients achieve complete remission ( CR ) 2 course receive higher-dose brentuximab vedotin IV 60 minute day 1 2 additional course . After completion study treatment , patient follow 21 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Patients must histologically document cytologically confirm Hodgkin lymphoma CD 30 expression Patients must absolute neutrophil count ( ANC ) &gt; = 1000/uL ; neupogen ( filgrastim ) give prior start SGN35 ( brentuximab vedotin ) SGN35 treatment achieve target ANC &gt; = 1000/uL Patients must platelets ( Plts ) &gt; = 50,000/uL ; platelet transfusion give prior start SGN35 SGN35 treatment achieve target plt &gt; = 50,000/uL Patients must measurable disease &gt; 1.5 cm evidence compute tomography ( CT ) scan neck/chest/abdomen ( abd ) /pelvis CT/positron emission tomography ( PET ) scan Patient must either primary refractory one frontline induction therapy relapse one frontline induction therapy ; patient achieve complete remission induction therapy also eligible Patients second line salvage treatment ( chemotherapy , biologic agent , investigational drug , radiation ) autologous allogeneic hematopoietic stem cell transplantation ; patient mixed frontline therapy 24 cycle ABVD ( doxorubicin , bleomycin , vinblastine dacarbazine ) follow 24 cycle bleomycin , etoposide , doxorubicin , cyclophosphamide , vincristine , procarbazine , prednisone ( BEACOPP ) long induction chemotherapy 8 cycle total length Radiation use part induction regimen consolidation ( within 90 day completion induction chemotherapy ) allow Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study Male subject agree use acceptable method contraception duration study Life expectancy great 3 month Karnofsky performance status &gt; 60 % ANC &gt; = 1000/uL Plts &gt; = 50,000/uL Total bilirubin within 1.5 x upper limit normal ( ULN ) institutional limit , patient elevation unconjugated bilirubin alone , Gilbert 's disease , eligible Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 2.5 X institutional ULN ( unless demonstrate Hodgkin lymphoma involvement liver ) Calculated creatinine clearance &gt; 30 ml/min ( unless demonstrate Hodgkin lymphoma involvement kidney ) ELIGIBILITY FOR 2.4 MG/KG DOSING IN THE NEW COHORT : In addition inclusion/exclusion criterion outline , eligible treatment high 2.4 mg/kg dose brentuximab vedotin new cohort 20 additional patient , best response 2 cycle brentuximab vedotin administered 1.8 mg/kg dose , must partial remission ( PR ) stable disease ( SD ) determine radiographic image Patient &gt; 1.5 x ULN total bilirubin , unless history Gilbert 's syndrome Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality ; prior study entry , electrocardiogram ( ECG ) abnormality screen document investigator medically relevant Patient hypersensitivity brentuximab vedotin Female subject pregnant breastfeeding ; confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening ; pregnancy test require postmenopausal surgically sterilize woman Patient receive investigational drug within 14 day treatment treatment brentuximab vedotin Serious medical psychiatric illness likely interfere participation clinical study Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Patients active malignancy ( evidence cancer life expectancy great 5 year ) ineligible study Patients active central nervous system ( CNS ) disease history brain metastasis ( mets ) exclude study Patients may steroids prior initiation treatment long cycle 1 day 1 steroid use taper less equal 20 mg prednisone .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>